Brigatinib Dose Rationale in Anaplastic Lymphoma...

CPT: Pharmacometrics & Systems Pharmacology 2020 / 11

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer: Exposure‐Response Analyses of Pivotal ALTA Study

Gupta, Neeraj, Wang, Xiaohui, Offman, Elliot, Rich, Benjamin, Kerstein, David, Hanley, Michael, Diderichsen, Paul Matthias, Zhang, Pingkuan, Venkatakrishnan, Karthik
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
CPT: Pharmacometrics & Systems Pharmacology
DOI:
10.1002/psp4.12569
Date:
November, 2020
File:
PDF, 16.85 MB
2020
Conversion to is in progress
Conversion to is failed